Abstracts tagged "methotrexate"

Abstract Number: 1710 • ACR Convergence 2021
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
Daniel Aletaha¹, Rene Westhovens², Tatsuya Atsumi³, YingMeei Tan⁴, Alena Pechonkina⁵, Qi Gong⁵, Vijay Rajendran⁶, Sander Strengholt⁷ and Gerd Burmester⁸, ¹Medical University Vienna, Vienna, Austria, ²University Hospitals KU Leuven, Maaseik, Belgium, ³Hokkaido University, Sapporo, Japan, ⁴Gilead Sciences, Inc, San Diego, CA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos, BV, New York, NY, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
Abstract Number: 0019 • ACR Convergence 2021
Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate
Laura Nuño¹, Alejandro Villalba¹, Marta Novella-Navarro², Irene Monjo¹, Diana Peitado¹, Sara Garcia-Carazo¹, Alejandro Balsa² and Maria-Eugenia Miranda-Carus¹, ¹Hospital La Paz - IdiPAZ, Madrid, Spain, ²Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: Inhibition of AICAR transformylase by MTX results in augmented release of adenine nucleotides to the extracellular space; these are rapidly hydrolysed by ectonucleotidases CD39…
Abstract Number: 0786 • ACR Convergence 2021
Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with Inflammatory Arthritis on Treatment with Methotrexate (MTX)
Saman Darabian¹, john Wade², Stefanie Wade³, Jason Kur² and Maziar Badii², ¹University of British Columbia, North Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Methotrexate (MTX) is often the primary medication to treat various rheumatic diseases, including rheumatoid arthritis, psoriasic arthritis and many other inflammatory diseases. MTX is…
Abstract Number: 1227 • ACR Convergence 2021
Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
Stephanie Duong¹, Cynthia Crowson², Elizabeth Atkinson¹, Arjun Athreya¹, John Davis¹, Eric Matteson³, Richard Weinshilboum¹, Liewei Wang¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Methotrexate (MTX) is the preferred initial disease-modifying drug (DMARD) for rheumatoid arthritis (RA). However, up to 50% of patients respond inadequately to MTX. Clinically…
Abstract Number: 1649 • ACR Convergence 2021
Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder
Tomohiro Kameda¹, Shusaku Nakashima¹, Hiromi Shimada¹, Risa Wakiya¹, Mai Fahmy Mansour¹, Mikiya Kato¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi², ¹Kagawa University, Takamatsu, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan
Background/Purpose: Methotrexate associated lymphoproliferative disorder (MTX-LPD) has various histological types from benign and malignant. Some MTX-LPDs spontaneously regress after discontinuation of MTX, even though they…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].